Pharma News

Glenmark Pharmaceuticals Limited a global, innovation-driven pharmaceutical company and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

A team of scientists has developed a new technology, platform for fluorometric detection of pathogens such as viruses by measurement of fluorescent light emitted. The potential of the new technology has been demonstrated for the detection of SARS-CoV-2. This technology platform can also be used to detect other DNA/RNA pathogens such as HIV, influenza, HCV, Zika, Ebola, bacteria, and other mutating/evolving pathogens.

The National Health Authority (NHA) under its flagship scheme of Ayushman Bharat Digital Mission (ABDM) announced completion of 27 major integrations across Government and private sector. These integrations with organizations offering Health Management Information Systems (HMIS), Laboratory Management Information Systems (LMIS), health locker services, health tech services and other digital services are a step towards developing a user-inclusive, integrated and interoperable digital healthcare eco-system for the country.

Wockhardt Limited has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

Wockhardts Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.

Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation lived more often when randomized to receive baricitinib. Doctors call this drug bari, and receiving the pill once a day for up to 14 days yielded one of the largest a survival advantages seen yet in the COVID pandemic, according to a study published.

A revolutionary pacemaker that re-establishes the hearts naturally irregular beat is set to be trialled in New Zealand heart patients this year, following successful animal trials. Currently, all pacemakers pace the heart metronomically, which means a very steady, even pace. But when you record heart rate in a healthy individual, you see it is constantly on the move, says Professor Julian Paton, a lead researcher and director of Manaaki Manawa, the Centre for Heart Research at the University of Auckland.

Two years into the pandemic, health systems are still facing significant challenges in providing essential health services. Ongoing disruptions have been reported in over 90 percent of countries surveyed in the third round of WHOs Global pulse survey on continuity of essential health services during the COVID-19 pandemic.

The U.S. Food and Drug Administration FDA has approved Enjaymo sutimlimab-jome to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease CAD. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells hemolysis.

Medidata, a Dassault Systèmes company, announced today that Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership. This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralized clinical trial technology (DCT) for the life sciences industry.